Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

RCKT Jan 19 '24 25.00 Call

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [N/A]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ rootItem.symbol ]]underlying price [[ rootItem.lastPrice ]] [[ rootItem.priceChange ]] ([[ rootItem.percentChange ]]) [[ rootItem.tradeTime ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Full Chart

Most Recent Stories

More News
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) Business Wire - Fri Mar 27, 6:00AM CDT

First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2 Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency...

RCKT : 3.46 (-2.54%)
Rocket Pharmaceuticals: Q4 Earnings Snapshot AP - Thu Feb 26, 3:06PM CST

Rocket Pharmaceuticals: Q4 Earnings Snapshot

RCKT : 3.46 (-2.54%)
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress Business Wire - Thu Feb 26, 3:00PM CST

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI ™ for severe LAD-I on track for March 28, 2026 PDUFA date ...

RCKT : 3.46 (-2.54%)
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire - Mon Feb 23, 6:00AM CST

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need,...

RCKT : 3.46 (-2.54%)
Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference Business Wire - Mon Jan 5, 6:00AM CST

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need,...

RCKT : 3.46 (-2.54%)
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference Business Wire - Tue Nov 25, 2025

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need,...

RCKT : 3.46 (-2.54%)
Rocket Pharmaceuticals: Q3 Earnings Snapshot AP - Thu Nov 6, 2025

Rocket Pharmaceuticals: Q3 Earnings Snapshot

RCKT : 3.46 (-2.54%)
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress Business Wire - Thu Nov 6, 2025

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date ...

RCKT : 3.46 (-2.54%)
Biologics Market Surges Toward $680B as FDA Accelerates Approval Pathways BayStreet.ca - Tue Nov 4, 2025

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The global biologics industry is experiencing unprecedented expansion as the market surges toward $679.56...

AVAI : 0.2900 (-3.30%)
VRTX : 434.30 (-1.01%)
WST : 256.85 (+0.80%)
RCKT : 3.46 (-2.54%)
AXSM : 169.74 (+0.73%)
Rocket Pharmaceuticals’ FDA Resubmission for KRESLADI™ Accepted Tipranks - Wed Oct 15, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Rocket Pharmaceuticals...

RCKT : 3.46 (-2.54%)
More news for this symbol

RCKT Related stocks

Symbol Latest 3M %Chg
RCKT 3.46 -2.26%
Rocket Pharmaceuticals Inc
AZN 202.83 +6.80%
Astrazeneca Plc
AMGN 342.57 +3.76%
Amgen Inc
GILD 140.13 +15.47%
Gilead Sciences Inc
BMY 59.33 +9.02%
Bristol-Myers Squibb Company
GSK 56.37 +11.49%
Gsk Plc ADR

Business Summary

Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States....

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.